US Edition
Dash Bio Secures $11M to Accelerate a New Era in Bioanalysis -- Bringing Total Funding to $17.5M
Summary by Intelligence360 News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Dash Bio Secures $11M to Accelerate a New Era in Bioanalysis -- Bringing Total Funding to $17.5M
Dash’s Fully Automated Bioanalysis Platform Is Reshaping Drug Development with Speed, Precision, and Scale NEWTON, Mass., July 23, 2025 /PRNewswire/ — Dash Bio, a preclinical and clinical bioanalysis company reinventing the speed and scalability of drug development, today announced it has raised an additional $11 million in funding, bringing its total raised to $17.5 million. The new financing was led by The Aligned Fund, with participation from…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
